TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04567108

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintain usual SSBs
Description: Instruction/guidelines to maintain baseline intake of SSBs (months 0-6); then switch to water only (months 6-12)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substitute to non-SSBs
Description: Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substitute to non-SSBs
Description: Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substitute to non-SSBs
Description: Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substitute to non-SSBs
Description: Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Study app
Description: Engage with a motivational mobile app to track beverage intake and complete study data collection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study app
Description: Engage with a motivational mobile app to track beverage intake and complete study data collection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study app
Description: Engage with a motivational mobile app to track beverage intake and complete study data collection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study app
Description: Engage with a motivational mobile app to track beverage intake and complete study data collection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study app
Description: Engage with a motivational mobile app to track beverage intake and complete study data collection

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beverage delivery
Description: Select from approved beverages for a monthly at-home delivery (months 0-6)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage delivery
Description: Select from approved beverages for a monthly at-home delivery (months 0-6)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage delivery
Description: Select from approved beverages for a monthly at-home delivery (months 0-6)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage delivery
Description: Select from approved beverages for a monthly at-home delivery (months 0-6)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage delivery
Description: Select from approved beverages for a monthly at-home delivery (months 0-6)
Study: NCT06461130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: Group of people doing dual tasks during double-leg cycling training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The group that received only aerobic exercise.
Study: NCT05290831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalPatch
Description: The VitalPatch continuously monitors skin temperature, activity, and electrocardiography.
Study: NCT05166044

Intervention type: BIOLOGICAL
Intervention: EV71 Inactivated Vaccine
Description: The EV71 vaccine was manufactured by Sinovac Biotech Co,And inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
Study: NCT04852016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consent process with the addition of Digital educational platform (DEP)
Description: In-patients being consented for laparoscopic cholecystectomy will be provided with a Digital Educational Platform (DEP), in the form of modules on an iPad. These participants will still undergo the usual standard verbal consent (SVC). Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using DEP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consent process using the standard verbal consent (SVC)
Description: In-patients being consented for laparoscopic cholecystectomy will go through the SVC. Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using SVC.
Study: NCT06326398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stoma Care
Description: Nursing students practice stoma care with low and high fidelity simulation
Study: NCT04717726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Description: Participants in the EX, EX + MT, and EX + LAC groups will complete five weekly exercise sessions on their own, expending roughly 600 kcal per session. Participants will be provided a Polar A-300 heart rate monitor programmed for their individual attributes (height, weight, age, training status, gender), which gives a real-time estimate of energy expenditure during exercise. Participants will report to the lab once per week to download the exercise sessions and verify compliance. If participants are not compliant (defined as completing 85% of their assigned exercise sessions per month), they will be disqualified. This intervention has been successfully used by Dr. Flack in multiple studies to produce significant weight loss without dietary intervention in this population with a retention rate of over 90%

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (CON)
Description: Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control (CON)
Description: Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.
Study: NCT04578327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic hand
Description: Different types of conventional prosthetic limbs will be used by subjects.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Interface
Description: Different types of peripheral nerve stimulation will take place
Study: NCT05496374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 500 mg
Description: SPR720 500 mg (250 mg × 2 capsules) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 500 mg
Description: SPR720 500 mg (250 mg × 2 capsules) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 1000 mg
Description: SPR720 500 mg (250 mg × 4 capsules) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 1000 mg
Description: SPR720 500 mg (250 mg × 4 capsules) will be administered orally.
Study: NCT04960865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping under tension.
Description: Kinesio tape will be applied to participants under tension.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesio Tape without tension
Description: Kinesio tape will be applied to participants without any tension.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rigid Taping
Description: Rigid Taping will be applied.
Study: NCT01204827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C Methacetin Breath Test (BreathID)
Study: NCT05720533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Combined With Sintilimab
Description: Disitamab Vedotin injection：2.5mg/kg，IV，Q3W Sintilimab injection：200mg，IV, Q3W
Study: NCT05117892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training, certification and marketing scheme
Description: The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
Study: NCT06339593

Intervention type: DRUG
Intervention: Hyperpolarized Xe129
Description: Hyperpolarized Xe MRI is FDA Approved for Adults and Children 12 and above We have been performing Xe MRI for research in human subjects for over 20 years, and for over 10 years at CCHMC. Recent FDA approval of hyperpolarized Xe MRI for ventilation stands as a testament to its safety and value as a modern tool for exploring lung disease and function. Earlier studies using Xe MRI have shown its efficacy in exploring CF and other lung diseases in pediatric and adult populations, and it has been found to be much more sensitive to early lung disease than traditional metrics like spirometry and MBW
Study: NCT05387265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-904
Description: CX-904 is a T-cell engaging bispecific Probody® candidate against Epidermal Growth Factor Receptor (EGFR) and CD3.
Study: NCT05788367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The pericapsular nerve group
Description: patients received Ultrasound guided pericapsular nerve group block using 20 ml of bupivacaine 0.5%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia
Study: NCT06158984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL
Description: Intense pulse light (IPL) therapy is used for the treatment of drug-related dry eye in glaucoma patients.
Study: NCT05919693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration
Study: NCT04616287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological assessment and Multimodal brain MRI
Description: Neuropsychological assessment and Multimodal brain MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment and Multimodal brain MRI
Description: Neuropsychological assessment and Multimodal brain MRI

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neuropsychological assessment and Multimodal brain MRI
Description: Neuropsychological assessment and Multimodal brain MRI
Study: NCT06720259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxantel Pamoate
Description: Tablets containing 250 mg oxantel pamoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxantel Pamoate
Description: Tablets containing 250 mg oxantel pamoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole
Description: Tablets containing 500 mg mebendazole
Study: NCT06720948

Intervention type: DEVICE
Intervention: ION 3D Facet Screw System
Description: Observational study of subjects previously implanted with ION 3D Facet Screw System.

Intervention type: DEVICE
Intervention: ION 3D Facet Screw System
Description: Observational study of subjects previously implanted with ION 3D Facet Screw System.
Study: NCT06732375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Reminders
Description: RR™ includes: 1) CBT; 2) resilience training; 3) mindfulness-based stress reduction; 4) peer support; and 5) family conversations delivered in small virtual groups, with a mentor who facilitates resilience-building conversations prompted from Skill of the Week lessons.
Study: NCT05352802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program
Description: Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERAS protocol
Description: The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
Study: NCT06225167

Intervention type: BEHAVIORAL
Intervention: To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
Description: To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.~To compare the incidence of overt GI bleeds (defined as hematemesis, bloody nasogastric tube aspirate, or melena) between patients who were on stress ulcer prophylaxis versus patients whose acid suppression therapy was discontinued through the stress ulcer prophylaxis minimization protocol.

Intervention type: BEHAVIORAL
Intervention: To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
Description: To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.~To compare the incidence of overt GI bleeds (defined as hematemesis, bloody nasogastric tube aspirate, or melena) between patients who were on stress ulcer prophylaxis versus patients whose acid suppression therapy was discontinued through the stress ulcer prophylaxis minimization protocol.
Study: NCT05621486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B4T2-001 Autologous CAR T cells
Description: Each subject will receive infusion with B4T2-001 autologous CAR T Cells
Study: NCT05351255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Aim 2 of the study includes an intervention where participants receive a repetitive TMS protocol called theta burst stimulation (TBS) to study its effect on motor learning behavior.
Study: NCT03244072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Intracameral injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intracameral injection
Study: NCT05482048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise as Airway Clearance Therapy (ExACT)
Description: Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET). The undertaking of ExACT at least once per day is expected.~Written and verbal instruction will be provided on the type, duration, frequency and intensity of exercise that is considered adequate replacement for routine chest physiotherapy. A compendium of allowable activity types, and the required times at different intensities that are considered to replace chest physiotherapy for ACT The research team will support exercise advice in line with standard care if subjects request this. The trial has no other changes to CF care. All medications, nutritional support and other treatments continue.
Study: NCT05671289

Intervention type: DIAGNOSTIC_TEST
Intervention: analysis of urine volatile organic compounds
Description: gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: analysis of urine volatile organic compounds
Description: gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
Study: NCT05030779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions CD19/BCMA CAR T-cells
Description: Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
Study: NCT06444906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermacyte Matrix
Description: The appropriate square centimeters of Dermacyte Matrix is applied directly to the target DFU that is free of debris and necrotic tissue. The Dermacyte Matrix will be applied at weekly intervals or for up to 10 applications.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: SOC therapy will consist of debridement of nonviable tissue, saline-moistened non-occlusive dressing, weight off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated at weekly intervals or for up to 10 applications.
Study: NCT05239130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auralya
Description: Auralya® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation. Auralya® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile glass syringe with a Luer adapter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auralya
Description: Auralya® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation. Auralya® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile glass syringe with a Luer adapter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auralya
Description: Auralya® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation. Auralya® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile glass syringe with a Luer adapter.
Study: NCT05014386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Glaucoma Valve Implantation in secondary pediatric glaucomas.
Description: A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Glaucoma Valve Implantation with Ologen augmentation in secondary pediatric glaucomas
Description: A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
Study: NCT04498130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-Week Home Exercise Group
Description: 12 week home-based program consisting of: weekly Zoom group chats; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Comparison Group
Description: 12 week home-based program consisting of: weekly check-in phone calls; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page.
Study: NCT04296695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/3TC/EFV
Description: TDF/3TC/EFV